DISRUPTIVE PDT TECHNOLOGY
Our revolutionary DigiLum™ solution presents a new paradigm in PDT administration and effectiveness, combining advanced AI-driven photonics with a next-generation photosensitizer agent. Unlike legacy PDT offerings, this powerful platform is readily adoptable and promises to unlock the potential of PDT to treat a broader range of cancer sites and extend the benefits of this more tolerable therapy to a greater number of patients.
Closing The Loop on PDT Light Activation
Our advanced photonics light delivery and dosimetry system leverages innovative device technology demonstrated by Roswell Park Cancer Center that is unique in allowing direct measurement of light interaction with target tissue. This enables automated, real-time light monitoring and closed loop control of light delivery with precise dosimetry. Our instrument presents a new level of sophistication by incorporating machine learning algorithms and use of calibration files based on actual tissue properties and light propagation effects of specific media in the procedure setting for unprecedented precision of PDT light dosimetry. Our DigiLum™ system represents the first true PDT light dosimetry system based on real-time data that is fully automated for ease of use, eliminating operator dependencies for repeatable, reliable clinical results. Furthermore, our novel device technology allows integration of multiple light emitting and detecting fiber optics over a broad exposure area to greatly reduce light activation procedure time- from hours to minutes in the case of lung/pleural PDT using DigiLum™.
5-Aminolevulinic Acid (5-ALA/Gleolan™)- The Ideal Photosensitizer
While our DigiLum™ system can be designed to activate any photosensitizer, our focus is on use of 5-ALA, a next generation agent with a known safety profile that is highly selective to tumor tissue for minimum off-target effects with negligible post-procedure phototoxicity- 24 hours compared to 30+ day of the current approved agent used in lung cancer. It offers a short time between drug administration and light activation that is more amenable to surgical procedure workflows. 5-ALA (marketed in the US as Gleolan™) is currently approved in 42 countries as an imaging agent for fluorescence-guided glioma surgery. It has the unique potential beyond imaging to also be used as a therapeutic agent, enabling intraoperative “see and treat” applications during surgical procedures.
